

Engagement in Risk Reduction Practices Following the Detection of Unexpected Drugs in Community Drug Checking Samples: A Cross-Sectional Study

Samuel Tobias,^{1,2} Cameron Grant,¹ Mark Lysyshyn,^{1,3}
Perrine Roux,⁴ Evan Wood,^{1,2} Thomas Kerr,^{1,2}
Lianping Ti,^{1,2}

1. British Columbia Centre on Substance Use, Vancouver, Canada;
2. University of British Columbia, Vancouver, Canada;
3. Vancouver Coastal Health, Vancouver, Canada;
4. SESSTIM, Marseille, France



Overview of drug checking services in BC

- Pilot began in October 2017 as a response to the growing drug toxicity crisis
- Services operate out of select supervised consumption sites, overdose prevention sites, and other sanctioned sites
- **Point-of-care:** Fourier-transform infrared spectroscopy + fentanyl, benzodiazepine, and xylazine immunoassay strips
- **Confirmatory analysis:** qNMR/GC-MS/LC-MS at a lab



Drug checking in progress



Fourier-transform infrared (FTIR) spectrometer

Methods

- Cross-sectional survey conducted in-person or by phone
- Conducted between March 2020 and July 2024
- Recruitment at 22 community harm reduction sites
- All participants used drug checking services in the last 6 months


- Relevant questions based on most recent drug check:

Exposure ➤ *What drug did you check?*
➤ *What were the results?*


Outcome ➤ *What did you do with your drugs when you got your results?*

- Multivariable logistic regression controlled for variables we believed to be associated with the relationship

Study sample (n=447)



- Median age of **43 years**
- **33%** women, **66%** men; **2%** gender minority
- **73%** White, **27%** Indigenous, Black, Person of Colour
- **30%** unhoused



- **69%** checked an opioid, **31%** checked a stimulant
- **81%** \geq weekly stimulant use
- **79%** \geq weekly opioid use

Results

Unexpected active drugs and engagement in a risk reduction behaviour

- $n = 438$
- **39%** reported an unexpected active drug in their sample
 - **20%** of these were in the absence of the expected drug
- Risk reduction practice
 - **24%** (w/ unexpected drugs present) vs. **14%** (w/o)

Model (Unexpected active drug vs. not)	Odds Ratio	95% Confidence Interval	p-value
Unadjusted model	2.03	1.24 – 3.31	0.005
Adjusted model*	2.24	1.30 – 3.87	0.004
Sensitivity analysis**	2.59	1.35 – 4.97	0.004

*Adjusted for age, gender, unregulated opioid use, stimulant use, regular source of drugs, drug checked was an opioid, drug checked was a stimulant

**Sensitivity analysis categorizes 'sold' and 'gave away drug' as risk reduction practices where the original definition did not

Limitations




- Non-random recruitment may limit generalizability
- Potential reporting biases
 - Recall bias
 - Social desirability bias
- Cross-sectional nature limits causal inference

Conclusion



- When unexpected, active drugs were detected in a drug checking sample, participants were **2.24 times more likely** to engage in a risk reducing behaviour
- These findings:
 - reinforce the value of drug checking technologies capable of detecting a wide spectrum of components
 - suggest opportunities for more tailored harm reduction messaging

Acknowledgements



We offer thanks to those individuals who participated in this study with the hopes that this involvement will contribute to utilizable public health information, improved harm reduction care, and potentially, decreased loss of life. We would also like to thank researchers and staff at various community organizations and health authorities across province for their work in this area. This research was conducted across the traditional, unceded territories of over 200 First Nations.

The study was supported by the US National Institutes of Health-National Institute on Drug Abuse (R01DA052381).

Samuel Tobias is supported by a Canadian Institutes of Health Research Canada Graduate Scholarship.

Thank you

samuel.tobias@bccsu.ubc.ca
drugcheckingBC.ca

BRITISH COLUMBIA CENTRE ON
SUBSTANCE USE

400-1045 Howe St
Vancouver BC
V6Z 2A9
www.bccsu.ca